



February 2, 2023

The General Manager
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001
Scrip Code: 500770

The Manager, Listing Department
The National Stock Exchange of India Limited
Exchange Plaza
Bandra-Kurla Complex
Bandra (E)
Mumbai 400 051
Symbol: TATACHEM

Dear Sir/Madam,

Sub: Newspaper Advertisement - Audited Standalone and Unaudited Consolidated Financial Results for the third quarter and nine months ended December 31, 2022

The Board of Directors at its Meeting held on February 1, 2023 has, *inter alia*, approved the Audited Standalone and Unaudited Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2022.

As per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said financial results were published in the following newspapers on February 2, 2023:

- i. Business Standard (English)
- ii. The Free Press Journal (English)
- iii. Navshakti (Marathi)

A copy of the results published is attached herewith. These are also being made available on the website of the Company at www.tatachemicals.com.

You are requested to take the same on record.

Thanking you,

**Yours faithfully,
For Tata Chemicals Limited**

**Rajiv Chandan
General Counsel & Company Secretary**

Encl.: a/a

TATA CHEMICALS LIMITED

Bombay House 24 Homi Mody Street Fort Mumbai 400 001
Tel 91 22 6665 8282 Fax 91 22 6665 8143/44 www.tatachemicals.com
CIN : L24239MH1939PLC002893

TP SOUTHERN ODISHA DISTRIBUTION LIMITED
(Procurement Department)
Call Center/Training Center, Duduma Colony,
Ambagada, Berhampur, Odisha-760001

NOTICE INVITING TENDER Date: 02.02.2023

TP Southern Odisha Distribution Limited (TPSODL) invites tender from eligible vendors for following:

Sl. No.	Tender Description	NIT Number	EMD (Rs. Lakh)	Tender Fee inclusive of GST (Rs.)	Last date and time of Payment of Tender Fee
1.	Procurement of VMWare cloud suite standard 2019 & Support for 01 year.	TPSODL/OT/2022-23/121	0.50	5,000/-	13.02.2023 17:00 Hrs
2.	Microsoft SQL Server Enterprise 02 Core License with Warranty Support of 3 years SITC and training of On Prem Microsoft Exchange Server & User CAL with Warranty Support of 1 year	TPSODL/OT/2022-23/122	1.00	5,000/-	13.02.2023 17:00 Hrs

For detailed tender, please visit Tender Section on TPSODL website
<https://www.tpsouthernodisha.com>

sidbi
SMALL INDUSTRIES DEVELOPMENT BANK OF INDIA
GeM Bid NOTICE

SIDBI invites eligible bidders to submit bids in GeM Portal for following bids:

Bid Description	GeM Bid Reference No.
Procurement of managed extended detection and response solution	GEM/2023/B/3042419 dated 02/02/2023

For detailed bid document, please visit www.sidbi.in Addendum/Corrigendum, if any, will be published in the above-mentioned websites only.

Bokaro Power Supply Co. (P) Ltd.
(A Joint Venture of SAIL & DVC)
Hall No. : M-01, Old Administrative Building
Ispat Bhavan, Bokaro Steel City-827001(Jharkhand)
CIN No. : U40300DL2001PTC112074

NOTICE INVITING EXPRESSION OF INTEREST

Ref. No. : BPSCL/MM/22-23/EOI-003/188 Date : 28.01.2023

BPSCL invites Expression of Interest (EOI) for **Revamping, Testing & Commissioning of existing dense phase pneumatic Ash Handling Plant of CPP Boiler.**

EOI is available at our website www.bpscl.com / etenders.gov.in. All corrigenda, amendments, time extensions etc., if any, will also be published in the same website. No separate notification shall be issued in the press. The applicants are requested to regularly visit the website to keep them updated.

Last date & time for submission of EOI : **14.03.2023 (12.00 Noon).**

For and on behalf of BPSCL
(A. K. Das)
CGM (MM)

RPG LIFE SCIENCES
An RPG Company

RPG LIFE SCIENCES LIMITED
Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.
CIN: L24232MH2007PLC169354;
Tel: +91-22-2498 1650; Fax: +91-22-2497 0127
E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com

Extract of Standalone Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2022
(Rs. in Lakhs)

Particulars	Quarter ended		Nine months ended		March 31, 2022 (Audited)
	Dec 31, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	Dec 31, 2022 (Unaudited)	Dec 31, 2021 (Unaudited)	
1 Total Income from Operations	13,060	11,558	39,432	33,636	44,016
2 Net Profit for the period (before tax, exceptional and extraordinary items)	2,574	2,062	7,787	6,224	7,317
3 Net Profit for the period before tax (after exceptional and extraordinary items)	2,574	2,062	7,787	6,224	7,317
4 Net Profit for the period after tax (after Exceptional and Extraordinary items)	1,911	1,463	5,729	4,396	5,148
5 Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	1,905	1,460	5,709	4,387	5,123
6 Paid-up equity share capital (Face Value Rs.8/- each)	1,323	1,323	1,323	1,323	1,323
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year	-	-	-	-	24,254
8 Earnings Per Share (Rs.8/- each) - (not annualised for the quarter):					
Basic (in Rs.):	11.56	8.85	34.64	26.58	31.13
Diluted (in Rs.):	11.56	8.85	34.64	26.58	31.13

Notes:

- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meetings held on February 01, 2023.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on Stock Exchange websites viz. (www.nseindia.com and www.bseindia.com) and on Company's website (www.rpglifesciences.com).

For RPG Life Sciences Limited
Yugal Sikri
Managing Director
DIN:07576560

Date : February 01, 2023
Place : Mumbai

Balaxi Pharmaceuticals Limited

Registered Office: Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598 | Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022
(Rs. in Lakhs, unless specified)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter ended 31/12/2022 Unaudited	Nine Months ended 31/12/2022 Unaudited	Quarter ended 31/12/2021 Unaudited	Quarter ended 31/12/2022 Unaudited	Nine Months ended 31/12/2022 Unaudited	Quarter ended 31/12/2021 Unaudited
1.	Total Income from Operations	2,306.81	7,778.64	1,795.3	8,658.17	25,575.14	6,172.36
2.	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	481.15	1,726.81	327.58	1,052.57	4,585.4	1,297.81
3.	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	481.15	1,726.81	327.58	1,052.57	4,585.4	1,297.81
4.	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	353.14	1,284.33	247.39	822.89	3,786.23	1,217.95
5.	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	353.14	1,284.33	247.39	846.92	4,382.9	1,220.74
6.	Paid-up Equity Share Capital [Face value of Rs. 10 each]	1,002.45	1,002.45	1,000.00	1,002.45	1,002.45	1,000.00
7.	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year			4,791.30			10316.42
8.	Earnings Per Share (of Rs.10/- each) (not annualised):						
	1. Basic (amount in Rs.)	3.52	12.83	2.47	8.21	37.83	12.18
	2. Diluted (amount in Rs.)	3.44	12.74	2.47	8.03	37.55	12.18

Notes:

- The above is an extract of the detailed format of Financial Results for the quarter and Nine Months ended 31st December, 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.
- The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 31st January, 2023 and 01st February, 2023, respectively. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of Board of Directors,
Balaxi Pharmaceuticals Limited
Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad
Date: 01st February, 2023

NIIF IFL INFRASTRUCTURE FINANCING
NIIF Infrastructure Finance Limited
("Formerly IDFC Infrastructure Finance Limited")

Registered Office: North Wing, 3rd Floor, UTI Tower, GN Block, Bandra Kurla Complex, Mumbai - 400 051, Maharashtra.
CIN No: U67190MH2014PLC253944 Website: www.niifi.in Tel. No: +91 22 68591300.

Statement of unaudited financial results for the nine month ended December 31, 2022
(₹ in crore)

Sr. No.	Particulars	Nine Months ended December 31, 2022	Nine Months ended December 31, 2021	Year ended March 31, 2022
		(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	1,033.02	697.94	977.19
2	Net Profit/(Loss) for the period (before tax, Exceptional and/or Extraordinary items)	240.22	178.05	233.25
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	240.22	178.05	233.25
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	240.22	178.05	233.25
5	Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	239.25	178.32	233.10
6	Paid-up equity share capital including redeemable preference shares	1,909.02	1,100.38	1,909.02
7	Reserves (excluding revaluation reserves)	1,445.16	947.92	1,205.92
8	Securities Premium Account	547.59	344.37	547.59
9	Net Worth	3,354.18	2,048.30	3,114.94
10	Paid-up Debt Capital/Outstanding Debt	14,360.50	9,634.61	12,322.74
11	Outstanding Redeemable Preference Shares	Nil	Nil	Nil
12	Debt Equity Ratio	4.28	4.70	3.96
13	Earnings per share (of ₹ 10 each) (for continuing and discontinuing operations) (not annualised)			
	Basic (₹)	1.75	1.78	2.31
	Diluted (₹)	1.75	1.78	2.31
14	Capital Redemption Reserve/Debt Redemption Reserve	Nil	Nil	Nil
15	Debt Redemption Reserve	Nil	Nil	Nil

Notes:

- The above is an extract of detailed format of Nine Month ended financials results filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The full format of the yearly financial results is available on www.nseindia.com & www.niifi.in. The above financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ("Ind AS") prescribed under Section 133 of the Companies Act, 2013. The Company has adopted Ind AS from April 1, 2018 with a transition date of April 1, 2017.
- The aforesaid financial results of the Company were reviewed by the Audit Committee on January 31, 2023 and approved by the Board of Directors at its meeting held on February 1, 2023.
- The debentures of the Company have been assigned rating of "AAA" by ICRA Limited & CARE Ratings Limited.
- The figures for previous period/year have been regrouped wherever required, to correspond with those of the current period/year.

For and on behalf of the Board of NIIF Infrastructure Finance Limited
Sd/-
Surya Prakash Rao Pendyala
Chairman

Date: February 01, 2023
Place: Mumbai

Ratios	Description	December 31, 2022
Debt-Equity Ratio	Total Debt / Total Equity	4.28
Current Ratio	NA	NA
Long Term Debt to Working Capital	NA	NA
Bad Debts to Account Receivable Ratio	NA	NA
Current Liability Ratio	NA	NA
Total Debts to Total Assets	Total Debt / Total Asset	0.81
Debtors Turnover	NA	NA
Inventory Turnover	NA	NA
Operating Margin (%)	Operating Profit / Total Revenue	23.15%
Net Profit Margin (%)	PAT / Total Revenue	23.16%
Net Worth (₹ in Crore)	Share capital + Reserves and surplus	3,354.18
Net Profit After Tax (₹ in Crore)		239.25
Earnings Per Share (Basic)	PAT / Total number of shares	1.75
Earnings Per Share (Diluted)	PAT / Total diluted number of shares	1.75
Gross/ Net Non-Performing Assets (NPAs)		Nil
Capital Redemption Reserve/Debt Redemption Reserve*	NA	NA

*Not applicable, being a Non-Banking Financial Service Company registered with the Reserve Bank of India.

TATA

Extracts of Statement of Consolidated Financial Results for the quarter and nine months ended 31 December, 2022
(₹ in crore)

Particulars	Quarter ended 31 December, 2022 (Unaudited)	Quarter ended 30 September, 2022 (Unaudited)	Quarter ended 31 December, 2021 (Unaudited)	Nine months ended 31 December, 2022 (Unaudited)	Nine months ended 31 December, 2021 (Unaudited)	Year ended 31 March, 2022 (Audited)
1. Revenue from continuing operations	4,148	4,239	3,141	12,382	9,141	12,622
2. Profit from continuing operations before exceptional items, share of profit of joint ventures and associate and tax	625	676	312	2,069	963	1,452
3. Profit from continuing operations after exceptional items, before share of profit of joint ventures and associate and tax	625	676	312	2,069	952	1,441
4. Profit from continuing operations before tax	534	723	406	2,054	1,154	1,667
5. Profit from continuing operations after tax	432	685	340	1,758	930	1,400
6. (Loss)/profit from discontinued operations before tax	(7)	(5)	10	(16)	37	18
7. (Loss)/profit from discontinued operations after tax	(7)	(5)	10	(16)	30	5
8. Profit for the period (5 + 7)	425	680	350	1,742	960	1,405
9. Total comprehensive income for the period	139	1,543	743	1,494	3,173	4,364
10. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255	255	255
11. Other equity and Non-controlling interests						18,902
12. Earnings per share						
- Basic and Diluted (for continuing operations) in ₹	15.62*	24.85*	11.82*	63.75*	31.00*	49.17
- Basic and Diluted (for discontinued operations) in ₹	(0.27)*	(0.20)*	0.37*	(0.63)*	1.17*	0.20
- Basic and Diluted (for continuing and discontinued operations) in ₹	15.35*	24.65*	12.19*	63.12*	32.17*	49.37
* Not annualised						

Extracts of Statement of Standalone Audited Financial Results for the quarter and nine months ended 31 December, 2022
(₹ in crore)

Particulars	Quarter ended 31 December, 2022	Quarter ended 30 September, 2022	Quarter ended 31 December, 2021	Nine months ended 31 December, 2022	Nine months ended 31 December, 2021	Year ended 31 March, 2022
1. Revenue from continuing operations	1,218	1,185	931	3,628	2,606	3,721
2. Profit from continuing operations before tax	244	277	213	1,016	672	988
3. Profit from continuing operations after tax	190	243	155	814	518	787
4. Profit from discontinued operations before tax	-	-	-	-	27	28
5. Profit from discontinued operations after tax	-	-	-	-	20	15
6. Profit for the period (3 + 5)	190	243	155	814	538	802
7. Total comprehensive income for the period	194	1,279	578	989	1,901	2,340
8. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255	255	255
9. Other equity						15,088
10. Earnings per share						
- Basic and Diluted (for continuing operations) in ₹	7.46*	9.54*	6.11*	31.95*	20.35*	30.87
- Basic and Diluted (for discontinued operations) in ₹	-	-	-	-	0.80*	0.59
- Basic and Diluted (for continuing and discontinued operations) in ₹	7.46*	9.54*	6.11*	31.95*	21.15*	31.46
* Not annualised						

Notes:

- The above is an extract of the detailed format of the Unaudited Consolidated and Audited Standalone financial results for the quarter and nine months ended 31 December, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Consolidated and Audited Standalone financial results for the quarter and nine months ended 31 December, 2022 is available on the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and on the Company's website (www.tatachemicals.com).
- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 1 February, 2023.

For and on behalf of the Board of
TATA CHEMICALS LIMITED
R. Mukundan
Managing Director and CEO

Place : Mumbai
Date : 1 February, 2023

TATA CHEMICALS LIMITED
Regd. Office : Bombay House, 24, Horni Mody Street, Fort, Mumbai - 400 001.
Tel: +91 22 66658282 Website: www.tatachemicals.com
CIN: L24239MH1939PLC002893 Email: investors@tatachemicals.com

गुडरन सहकारी गुहनिर्माण संस्था मर्यादित
नॅल्की ज. चव्हाण/इन्द्रप्रकाश/एचमणी
(टीसी)/१९९१/२००५-०६/सब २००६
दि. ०६.०३.२००५
पत्ता : सखे क्र. ३५०, न.मु.क्र. ६२२ (भा.प.)
शेजा नगर समो. बॅच. मुंबई-४०० ०१६

CORRIGENDUM
In continuation of tender notice published in free press Journal and Navshakti newspapers dated 20.01.2023 the date of tender submission is rescheduled and is now 9th Feb. 2023 from 11.00 am to 5.00 pm. The blank tender forms are available in the office of the PMC upto 5.00 pm of 08.02.2023.
Date : 31.01.2023
गुडरन सहकारी गुहनिर्माण संस्था मर्यादित
सही/-
अध्यक्ष

PUBLIC NOTICE
Notice is hereby given that (i) Mrs. Lata Shivkumar Acharya and (ii) Mr. Shivkumar Chattramal Acharya (the "Owners") are the owners of and/or seized and possessed off and/or otherwise well and sufficiently entitled to the under mentioned property. The Owners have agreed to grant development rights for redevelopment of the under mentioned property in favour of my client. Any person/entity having any claim/objection in respect of the under mentioned property or any portion or part thereof including claim/objection as and by way of development rights, TDR, sale, exchange, mortgage, gift, lien, trust, lease, possession, inheritance, easement, license or otherwise howsoever are hereby required to make the same known in writing along with certified true copy of supporting documents to the undersigned at the address mentioned below within 15 days from the publication hereof, failing which such right, title, benefit, interest, claim and/or demand, if any, shall be deemed to have been waived and abandoned.

THE SCHEDULE OF PROPERTY
ALL THAT non-agricultural land or ground, hereditaments and premises bearing Plot No.9, in the estate of The Greater Bombay Co-operative Housing Society Limited, adjoining 840.50 sq. meters or thereabouts, situate, lying and being at Gulmohar Cross Road No. 4, near Jhu Jhu Vile Parle Development Scheme, Vile Parle (West), Mumbai - 400049, bearing C.T.S. No. 9A/3/3/1 of Revenue Village Vile Parle (West), Taluka and Registration Sub District: Andheri, District Mumbai Suburban, within Greater Mumbai together with structure of silt and 3 (three) upper floors known as 'Namita' assessed to municipal rates and taxes at House No.8172(9), Street No.9 North of Irla Nala of K West Ward. Dated this 2nd day of February, 2023.
Sd/-
(Kunal S. Jain)
Advocate, High Court
Plot no. 569, Nira Vihar C.H.S.L., Unit no. 5, 1st Floor, 5th Road, Khar (West), Mumbai - 400 052
M: 989290294.
kunaljain2008@yahoo.com

गंधी स्पेशल ट्यूबज लि.
(सीआयएन - एल२०१०४एमएच१२८पीएलसी०३६००४)
नॉ. कार्यालय : २०१-२०४, पन्नाझा, २रा मजला, ५५, हनुमंत रोड, मुंबई-४०० ००७
दूर. : ११-२२-२३६३ ४१७२/२३६३ ४१८३/२३६३ ५०४४
ई-मेल : info@gandhitubes.com, वेबसाईट : www.gandhispecialtubes.com
३१ डिसेंबर, २०२२ रोजी संपलली तिमाही आणि नऊ महिन्याकरिता अलेखापरिष्कृत वित्तीय निष्कर्षांचा उतारा
(ईपीएस सोडून रु. लाखांत)

गंधी स्पेशल ट्यूबज लिमिटेड साठी
मनहर गांधी
अध्यक्ष आणि व्यवस्थापकीय संचालक
दिनांक : ३१ जानेवारी, २०२३

जाहीर सूचना
शाखा कार्यालय: आयसीआयसीआय बँक लि., लॅण्डमार्क बिल्डिंग, ४था मजला, २२८ए, एजेसी बॉस रोड, कोलकाता ७०००२०. सीआयएन क्र.: एल६५१९००जीजे१९१४पीएलसी०२१०१२. www.icicibank.com

खातील कर्जादारांनी बँकेकडून त्यांनी घेतलेल्या कर्जा सुविधेची पुढील आणि व्याजाचा परतवा करणारा केलेली आहे आणि कर्ज नोंद परफॉर्मिंग असेट्स (एपीपी) म्हणून वर्गीकृत झाले आहे. खालील नमूद ताखेची सूचना सिस्चुरिटीडिव्हिजन अँड रिस्कमॅनेज्मेंट ऑफ फायनान्सियल अँड इन्फोर्मेशन अँड सिस्चुरिटी इंटरस्ट अँड, २०२२ च्या कन्स १३(२) अन्वये त्यांनी दिलेल्या त्यांच्या शेवटच्या ज्ञात परतवावर त्यांना जारी करण्यात आली, तथापि ती न बजावता परत आली म्हणून त्यांना सदर जाहीर सूचनेद्वारे कळविण्यात येत आहे.

३१ डिसेंबर, २०२२ रोजी संपलेल्या तिमाही आणि नऊमाहीकरिता एकत्रित वित्तीय निष्कर्षांचा उतारा
(₹ कोटीत)

३१ डिसेंबर, २०२२ रोजी संपलेल्या तिमाही आणि नऊमाहीकरिता लेखापरिष्कृत अलिप्त वित्तीय निष्कर्षांचा उतारा
(₹ कोटीत)

PRIME SECURITIES LIMITED
Regd. Office : 1109/1110, Maker Chambers V, Nariman Point, Mumbai 400021
(CIN: L67120MH1982PLC026724)
Tel: +91-22-61842525 Fax: +91-22-24970777 Website: www.primsec.com Email: prime@primsec.com
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2022
[CONSOLIDATED] (₹s. Lakhs)

हिंदुस्तान हार्डी लिमिटेड
नोंदणी. कार्यालय : प्लॉट क्र. सी-१२, एम.आय.डी.सी. एरिया, अंबड, नाशिक-४२२०१०.
वेबसाईट : www.hardys.com, ई-मेल आयडी - info@hardys.com, सीआयएन : एल२१३००एमएच१२८पीएलसी०२८४९८
संपर्क - दूर. ०२५३-२३८२१९८, टेलिफॅक्स : ११-०२५३-२३८२५८.
३१.१२.२०२२ रोजी संपलेल्या तिमाहीकरिता अलेखापरिष्कृत वित्तीय निष्कर्ष
(₹ लाखांत, ईपीएस सोडून)

अलिप्त निष्कर्ष :
अ. क्र. तपशील
संपलेली तिमाही
३१-डिसें-२२ (अलेखापरिष्कृत) ३०-सप्टें-२२ (अलेखापरिष्कृत) ३१-डिसें-२२ (अलेखापरिष्कृत) ३१-डिसें-२१ (अलेखापरिष्कृत) ३१-मार्च-२२ (लेखापरिष्कृत)

केईसी इंटरनॅशनल लिमिटेड
सीआयएन - एल४५२००एमएच२००५पीएलसी१५२०६१
नोंदणीकृत कार्यालय : आरपीजी हाऊस, ४६३, डॉ. अनी बेडेंट रोड, वरळी, मुंबई - ४०००३०.
दूर. क्र. : ०२२-६६६७०२००, फॅक्स क्र. : ०२२-६६६७०२८७,
वेबसाईट : www.kecprg.com, ईमेल : investorpoint@kecprg.com
३१ डिसेंबर, २०२२ रोजी संपलेली तिमाही आणि नऊ महिन्यांकरिता एकत्रित अलेखापरिष्कृत वित्तीय निष्कर्षांचा उतारा
रु. कोटी मध्ये

३१ डिसेंबर, २०२२ रोजी संपलेल्या तिमाही आणि नऊमाहीकरिता लेखापरिष्कृत अलिप्त वित्तीय निष्कर्षांचा उतारा
(₹ कोटीत)

केईसी इंटरनॅशनल लिमिटेड साठी
सही/-
विमल केजरीवाल
व्यवस्थापकीय संचालक व सीईओ
दिनांक : ३१ जानेवारी, २०२३
आम्हाला भेट द्या www.kecprg.com